S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths

LivaNova Stock Price, News & Analysis (NASDAQ:LIVN)

$46.43
+1.36 (+3.02%)
(As of 12/8/2023 ET)
Compare
Today's Range
$44.77
$46.71
50-Day Range
$43.45
$53.66
52-Week Range
$40.26
$59.86
Volume
568,901 shs
Average Volume
628,132 shs
Market Capitalization
$2.50 billion
P/E Ratio
928.79
Dividend Yield
N/A
Price Target
$58.60

LivaNova MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
26.2% Upside
$58.60 Price Target
Short Interest
Bearish
4.12% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
36.28%
From $2.26 to $3.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

573rd out of 932 stocks

Electromedical Equipment Industry

11th out of 21 stocks


LIVN stock logo

About LivaNova Stock (NASDAQ:LIVN)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. It also engages in research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

LIVN Stock Price History

LIVN Stock News Headlines

Analyzing LivaNova (NASDAQ:LIVN) & Semler Scientific (NASDAQ:SMLR)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
LivaNova PLC (LIVN) Reports 13.3% Increase in Q3 Revenue
LivaNova Reports Third-Quarter 2023 Results
5 Analysts Have This to Say About LivaNova
LivaNova to Announce Third-Quarter 2023 Results
Amgen and Biogen 'look attractive' - HSBC
Stifel Nicolaus Sticks to Their Buy Rating for LivaNova (LIVN)
See More Headlines
Receive LIVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LivaNova and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/28/2024

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LIVN
Employees
2,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$58.60
High Stock Price Target
$62.00
Low Stock Price Target
$52.00
Potential Upside/Downside
+26.2%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-86,250,000.00
Pretax Margin
1.74%

Debt

Sales & Book Value

Annual Sales
$1.02 billion
Cash Flow
$6.50 per share
Book Value
$22.56 per share

Miscellaneous

Free Float
53,769,000
Market Cap
$2.50 billion
Optionable
Optionable
Beta
0.82
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. William A. Kozy (Age 71)
    Chairman of Board & Interim CEO
    Comp: $185k
  • Mr. Alex Shvartsburg (Age 52)
    Chief Financial Officer
    Comp: $852.2k
  • Ms. Trui Hebbelinck (Age 51)
    Chief Human Resources Officer
    Comp: $731.41k
  • Mr. Marco DolciMr. Marco Dolci (Age 61)
    President of Cardiopulmonary Business Unit
    Comp: $1.14M
  • Lindsey Little
    Senior Director of Investor Relations
  • Mr. Michael Hutchinson (Age 52)
    Senior VP, Chief Legal Officer & Company Secretary
  • Deanna Wilke
    Vice President of Corporate Communications
  • Mr. Matthew Joseph Dodds III
    Senior Vice President of Corporate Development & IT
  • Dr. Bryan D. Olin Ph.D. (Age 56)
    Senior VP & Head of Product Development - Neuromodulation
  • Mr. Ryan Miller
    President of Advanced Circulatory Support














LIVN Stock Analysis - Frequently Asked Questions

Should I buy or sell LivaNova stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" LIVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LIVN, but not buy additional shares or sell existing shares.
View LIVN analyst ratings
or view top-rated stocks.

What is LivaNova's stock price target for 2024?

5 brokerages have issued twelve-month target prices for LivaNova's shares. Their LIVN share price targets range from $52.00 to $62.00. On average, they expect the company's stock price to reach $58.60 in the next year. This suggests a possible upside of 26.2% from the stock's current price.
View analysts price targets for LIVN
or view top-rated stocks among Wall Street analysts.

How have LIVN shares performed in 2023?

LivaNova's stock was trading at $55.54 at the beginning of 2023. Since then, LIVN stock has decreased by 16.4% and is now trading at $46.43.
View the best growth stocks for 2023 here
.

When is LivaNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our LIVN earnings forecast
.

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) released its quarterly earnings results on Wednesday, November, 1st. The company reported $0.73 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.09. The firm had revenue of $286.10 million for the quarter, compared to analyst estimates of $271.97 million. LivaNova had a trailing twelve-month return on equity of 12.10% and a net margin of 0.27%. The company's quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the business earned $0.58 EPS.

What is Damien McDonald's approval rating as LivaNova's CEO?

47 employees have rated LivaNova Chief Executive Officer Damien McDonald on Glassdoor.com. Damien McDonald has an approval rating of 77% among the company's employees.

What other stocks do shareholders of LivaNova own?
Who are LivaNova's major shareholders?

LivaNova's stock is owned by many different institutional and retail investors. Top institutional investors include Primecap Management Co. CA (10.74%), Victory Capital Management Inc. (1.86%), Ameriprise Financial Inc. (1.70%), Loomis Sayles & Co. L P (1.63%), Hawk Ridge Capital Management LP (1.60%) and Barclays PLC (1.58%). Insiders that own company stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore and Marco Dolci.
View institutional ownership trends
.

How do I buy shares of LivaNova?

Shares of LIVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:LIVN) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -